Emerald Advisers LLC Has $2.96 Million Stock Position in Quanterix Co. (NASDAQ:QTRX)

Emerald Advisers LLC decreased its position in Quanterix Co. (NASDAQ:QTRX - Free Report) by 61.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 278,395 shares of the company's stock after selling 440,822 shares during the period. Emerald Advisers LLC owned approximately 0.72% of Quanterix worth $2,959,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in QTRX. Vanguard Group Inc. grew its holdings in Quanterix by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company's stock worth $23,569,000 after buying an additional 19,386 shares in the last quarter. Fox Run Management L.L.C. boosted its position in Quanterix by 258.7% during the 4th quarter. Fox Run Management L.L.C. now owns 43,784 shares of the company's stock worth $465,000 after acquiring an additional 31,577 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Quanterix in the fourth quarter worth $66,000. American Century Companies Inc. increased its holdings in shares of Quanterix by 9.1% during the fourth quarter. American Century Companies Inc. now owns 71,992 shares of the company's stock valued at $765,000 after purchasing an additional 6,023 shares during the period. Finally, William Blair Investment Management LLC bought a new stake in shares of Quanterix during the fourth quarter valued at about $11,290,000. Institutional investors and hedge funds own 86.48% of the company's stock.

Quanterix Stock Down 3.1 %

Quanterix stock traded down $0.21 during midday trading on Friday, hitting $6.56. The company's stock had a trading volume of 515,291 shares, compared to its average volume of 514,785. Quanterix Co. has a 12 month low of $6.30 and a 12 month high of $23.86. The stock's 50-day moving average price is $7.99 and its 200-day moving average price is $10.65. The company has a market capitalization of $254.37 million, a PE ratio of -6.19 and a beta of 1.33.

Remove Ads

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The company had revenue of $35.16 million for the quarter, compared to the consensus estimate of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. As a group, equities analysts anticipate that Quanterix Co. will post -0.98 EPS for the current year.

Analyst Ratings Changes

QTRX has been the subject of a number of recent analyst reports. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research report on Tuesday. Canaccord Genuity Group lowered their price objective on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.